A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Tissue-derived adenosine, acting via the adenosine A(2A) receptor (A(2A)R), is emerging as an important negative regulator of T-cell function. In this report, we demonstrate that A(2A)R stimulation not only inhibits the generation of adaptive effector T cells but also promotes the induction of adaptive regulatory T cells. In vitro, antigen recognition in the setting of A(2A)R engagement induces T-cell anergy, even in the presence of costimulation. T cells initially stimulated in the presence of an A(2A)R agonist fail to proliferate and produce interleukin-2 and interferon (IFN)-gamma when rechallenged in the absence of A(2A)R stimulation. Likewise, in an in vivo model of autoimmunity, tissue-derived adenosine promotes anergy and abrogates tissue destruction. Indeed, A(2A)R stimulation inhibits interleukin-6 expression while enhancing the production of transforming growth factor-beta. Accordingly, treating mice with A(2A)R agonists not only inhibits Th1 and Th17 effector cell generation but also promotes the generation of Foxp3(+) and LAG-3(+) regulatory T cells. In this regard, A(2A)R agonists fail to prevent autoimmunity by LAG-3(-/-) clonotypic T cells, implicating an important role for LAG-3 in adenosine-mediated peripheral tolerance. Overall, our findings demonstrate that extracellular adenosine stimulates the A(2A)R to promote long-term T-cell anergy and the generation of adaptive regulatory T cells.

[1]  D. Getnet,et al.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. , 2007, Blood.

[2]  H. Zarour,et al.  Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. , 2007, Cancer research.

[3]  V. Kuchroo,et al.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.

[4]  Liping Huang,et al.  Activation of Adenosine 2A Receptors Attenuates Allograft Rejection and Alloantigen Recognition1 , 2007, The Journal of Immunology.

[5]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[6]  C. Blobel,et al.  Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3 , 2007, The EMBO journal.

[7]  R. Khanna,et al.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. , 2006, Blood.

[8]  Courtney M. Lappas,et al.  Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis1 , 2006, The Journal of Immunology.

[9]  J. Powell The induction and maintenance of T cell anergy. , 2006, Clinical immunology.

[10]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[11]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[12]  Y. Wan,et al.  Transforming growth factor-β: Recent advances on its role in immune tolerance , 2006 .

[13]  T. Okazaki,et al.  The PD-1-PD-L pathway in immunological tolerance. , 2006, Trends in immunology.

[14]  Y. Wan,et al.  Transforming growth factor-beta: recent advances on its role in immune tolerance. , 2006, Current rheumatology reports.

[15]  Courtney M. Lappas,et al.  Adenosine A2A agonists in development for the treatment of inflammation , 2005, Expert opinion on investigational drugs.

[16]  K. Jacobson,et al.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. , 2005, Blood.

[17]  Jeanne Kowalski,et al.  Egr-2 and Egr-3 are negative regulators of T cell activation , 2005, Nature Immunology.

[18]  William L Redmond,et al.  Peripheral tolerance of CD8 T lymphocytes. , 2005, Immunity.

[19]  D. Vignali,et al.  Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1 , 2005, The Journal of Immunology.

[20]  Courtney M. Lappas,et al.  A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. , 2005, Journal of immunology.

[21]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[22]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[23]  A. Ohta,et al.  Cutting Edge: Physiologic Attenuation of Proinflammatory Transcription by the Gs Protein-Coupled A2A Adenosine Receptor In Vivo , 2004, The Journal of Immunology.

[24]  Manfred Thiel,et al.  Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. , 2004, Annual review of immunology.

[25]  G. Hartmann,et al.  Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. , 2004, Blood.

[26]  Jeanne Kowalski,et al.  Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes , 2004, Bioinform..

[27]  S. Anand,et al.  Control of autoimmune diseases by the B7-CD28 family molecules. , 2004, Current pharmaceutical design.

[28]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[29]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[30]  C. Drake,et al.  CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction , 2003, The Journal of Immunology.

[31]  M. Sitkovsky Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. , 2003, Biochemical pharmacology.

[32]  A. Gerbes,et al.  [Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage]. , 2002, Zeitschrift fur Gastroenterologie.

[33]  Anjana Rao,et al.  Transcriptional Mechanisms Underlying Lymphocyte Tolerance , 2002, Cell.

[34]  B. Cronstein,et al.  Inflammatory Cytokines Regulate Function and Expression of Adenosine A2A Receptors in Human Monocytic THP-1 Cells1 , 2001, The Journal of Immunology.

[35]  M. Idzko,et al.  Expression and function of adenosine receptors in human dendritic cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[37]  J. F. Chen,et al.  Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. , 2001, The Biochemical journal.

[38]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[39]  K. Tracey,et al.  High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes , 2000, The Journal of experimental medicine.

[40]  David W. Marsh,et al.  In Vivo CD4+ T Cell Tolerance Induction Versus Priming Is Independent of the Rate and Number of Cell Divisions1 , 2000, The Journal of Immunology.

[41]  R. Schwartz,et al.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.

[42]  J. Blay,et al.  The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.

[43]  M. Sitkovsky,et al.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. , 1997, Blood.

[44]  R. Schwartz,et al.  Reversal of in vitro T cell clonal anergy by IL-2 stimulation. , 1992, International immunology.

[45]  G. Schönrich,et al.  Non‐Deletional Mechanisms of Peripheral and Central Tolerance: Studies with Transgenic Mice with Tissue‐Specific Expression of a Foreign MHC Class I Antigen , 1991, Immunological reviews.

[46]  J. Lamb,et al.  Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. , 1988, Immunology.